The TFIID complex is a new autoantibody target in systemic sclerosis

Jean-Baptiste Vulsteke; Birthe Michiels; Vanessa Smith; Yves Piette; Marie Vanthuyne; Carole Lacout; Antoine Brochard; Mohammed Tikly; Jonas De Leeuw; Doreen Dillaerts; Tom Dehaemers; Petra De Haes; Jan L Lenaerts; Daniel Blockmans; Neil McHugh; Sarah Tansley; Emeline Vinatier; Frédéric Houssiau; Carolien Bonroy; Ellen De Langhe; Xavier Bossuyt

doi:10.1016/j.ard.2025.05.008

The TFIID complex is a new autoantibody target in systemic sclerosis

Jean-Baptiste Vulsteke, Birthe Michiels, Vanessa Smith, Yves Piette, Marie Vanthuyne, Carole Lacout, Antoine Brochard, Mohammed Tikly, Jonas De Leeuw, Doreen Dillaerts, Tom Dehaemers, Petra De Haes, Jan L Lenaerts, Daniel Blockmans, Neil McHugh, Sarah Tansley, Emeline Vinatier, Frédéric Houssiau, Carolien Bonroy, Ellen De LangheXavier Bossuyt

Research output: Contribution to journal › Letter › peer-review

50 Downloads (Pure)

Abstract

Systemic sclerosis (SSc) is characterised by systemic fibrosis, vascular dysfunction, and the presence of antinuclear autoantibodies. The major SSc-associated antinuclear antibodies include anticentromere, antitopoisomerase I, anti–RNA polymerase III and antifibrillarin autoantibodies [1]. These autoantibodies are generally mutually exclusive and define clinically relevant subgroups.

Original language	English
Journal	Annals of the Rheumatic Diseases
Early online date	19 Jun 2025
DOIs	https://doi.org/10.1016/j.ard.2025.05.008
Publication status	E-pub ahead of print - 19 Jun 2025

Acknowledgements

We thank An Knoops for performing the indirect immunofluorescence assay.

Funding

We thank An Knoops for performing the indirect immunofluorescence assay. J-BV, EDL, and XB designed the study. J-BV, XB, DD, BM, and TDH analysed the data. XB, BM and J-BV drafted the manuscript. J-BV, DD, BM, and TDH performed the IP-MS experiments. J-BV, VS, YP, PDH, JL, DB, CB, EDL, and XB collected patient data and revised the draft manuscript. All authors revised the draft manuscript. J-BV held a Research Foundation\u2014Flanders (FWO) SB Fellowship (1S62419N). This study was supported by the Research Fund KU Leuven (C3/20/042) and by FWO-Applied Biomedical research (TBM) (T004821N). VS is a Senior Clinical Investigator of the Research Foundation\u2013Flanders (Belgium) (FWO) [grant number 1802925N]. The samples from Leuven and from Angers were collected as part of a retrospective study using left-over material of samples submitted to the clinical laboratory (secondary use) for which an informed consent waiver was authorized by the Ethical Committee of the University Hospitals Leuven (Belgium) and of CHU Angers (France). Patients were notified of the content and aim of the study. All patients from Ghent university hospital (Belgium), Cliniques Universitaires Saint-Luc (Belgium) and Chris Hani Baragwanath Hospital (South Africa) signed informed consent. The study was approved by the local Ethical Committees: S60347/B32220071204, S65989 (University Hospitals Leuven); B67020084358 (Ghent University Hospital). MTA was in place between University Hospitals Leuven and Cliniques Universitaires Saint-Luc, Centre Hospitalier Universitaire d'Angers, and University of Bath. Not commissioned; externally peer reviewed. Patients were not involved in the design, or conduct, or reporting, or dissemination plans of our research. J-BV held a Research Foundation\u2014Flanders (FWO) SB Fellowship (1S62419N). This study was supported by the Research Fund KU Leuven (C3/20/042) and by FWO-Applied Biomedical research (TBM) (T004821N). VS is a Senior Clinical Investigator of the Research Foundation\u2013Flanders (Belgium) (FWO) [grant number 1802925N].

Funders	Funder number
EDL
CHU Angers
University Hospitals
Cliniques Universitaires Saint-Luc
Centre Hospitalier Universitaire d' Angers
University of Bath
Universitaire Ziekenhuizen Leuven, KU Leuven
Universitair Ziekenhuis Gent
Fonds Wetenschappelijk Onderzoek	1S62419N
Chris Hani Baragwanath Hospital	S60347/B32220071204, B67020084358, S65989
Research Fund KU Leuven	C3/20/042
FWO-Applied	1802925N, T004821N

ASJC Scopus subject areas

Rheumatology
Immunology and Allergy
Immunology
General Biochemistry,Genetics and Molecular Biology

Access to Document

10.1016/j.ard.2025.05.008

TFIID_Letter_with_revisions_finalAccepted author manuscript, 302 KBLicence: CC BY

Cite this

Vulsteke, J.-B., Michiels, B., Smith, V., Piette, Y., Vanthuyne, M., Lacout, C., Brochard, A., Tikly, M., De Leeuw, J., Dillaerts, D., Dehaemers, T., De Haes, P., Lenaerts, J. L., Blockmans, D., McHugh, N., Tansley, S., Vinatier, E., Houssiau, F., Bonroy, C., ... Bossuyt, X. (2025). The TFIID complex is a new autoantibody target in systemic sclerosis. Annals of the Rheumatic Diseases. Advance online publication. https://doi.org/10.1016/j.ard.2025.05.008

Vulsteke, J-B, Michiels, B, Smith, V, Piette, Y, Vanthuyne, M, Lacout, C, Brochard, A, Tikly, M, De Leeuw, J, Dillaerts, D, Dehaemers, T, De Haes, P, Lenaerts, JL, Blockmans, D, McHugh, N , Tansley, S, Vinatier, E, Houssiau, F, Bonroy, C, De Langhe, E & Bossuyt, X 2025, 'The TFIID complex is a new autoantibody target in systemic sclerosis', Annals of the Rheumatic Diseases. https://doi.org/10.1016/j.ard.2025.05.008

@article{f52786f22bfd4969904b2c796a16f035,

title = "The TFIID complex is a new autoantibody target in systemic sclerosis",

abstract = "Systemic sclerosis (SSc) is characterised by systemic fibrosis, vascular dysfunction, and the presence of antinuclear autoantibodies. The major SSc-associated antinuclear antibodies include anticentromere, antitopoisomerase I, anti–RNA polymerase III and antifibrillarin autoantibodies [1]. These autoantibodies are generally mutually exclusive and define clinically relevant subgroups.",

author = "Jean-Baptiste Vulsteke and Birthe Michiels and Vanessa Smith and Yves Piette and Marie Vanthuyne and Carole Lacout and Antoine Brochard and Mohammed Tikly and \{De Leeuw\}, Jonas and Doreen Dillaerts and Tom Dehaemers and \{De Haes\}, Petra and Lenaerts, \{Jan L\} and Daniel Blockmans and Neil McHugh and Sarah Tansley and Emeline Vinatier and Fr{\'e}d{\'e}ric Houssiau and Carolien Bonroy and \{De Langhe\}, Ellen and Xavier Bossuyt",

year = "2025",

month = jun,

day = "19",

doi = "10.1016/j.ard.2025.05.008",

language = "English",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - The TFIID complex is a new autoantibody target in systemic sclerosis

AU - Vulsteke, Jean-Baptiste

AU - Michiels, Birthe

AU - Smith, Vanessa

AU - Piette, Yves

AU - Vanthuyne, Marie

AU - Lacout, Carole

AU - Brochard, Antoine

AU - Tikly, Mohammed

AU - De Leeuw, Jonas

AU - Dillaerts, Doreen

AU - Dehaemers, Tom

AU - De Haes, Petra

AU - Lenaerts, Jan L

AU - Blockmans, Daniel

AU - McHugh, Neil

AU - Tansley, Sarah

AU - Vinatier, Emeline

AU - Houssiau, Frédéric

AU - Bonroy, Carolien

AU - De Langhe, Ellen

AU - Bossuyt, Xavier

PY - 2025/6/19

Y1 - 2025/6/19

N2 - Systemic sclerosis (SSc) is characterised by systemic fibrosis, vascular dysfunction, and the presence of antinuclear autoantibodies. The major SSc-associated antinuclear antibodies include anticentromere, antitopoisomerase I, anti–RNA polymerase III and antifibrillarin autoantibodies [1]. These autoantibodies are generally mutually exclusive and define clinically relevant subgroups.

AB - Systemic sclerosis (SSc) is characterised by systemic fibrosis, vascular dysfunction, and the presence of antinuclear autoantibodies. The major SSc-associated antinuclear antibodies include anticentromere, antitopoisomerase I, anti–RNA polymerase III and antifibrillarin autoantibodies [1]. These autoantibodies are generally mutually exclusive and define clinically relevant subgroups.

UR - http://www.scopus.com/inward/record.url?scp=105010346381&partnerID=8YFLogxK

U2 - 10.1016/j.ard.2025.05.008

DO - 10.1016/j.ard.2025.05.008

M3 - Letter

C2 - 40541453

SN - 0003-4967

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

ER -

The TFIID complex is a new autoantibody target in systemic sclerosis

Abstract

Acknowledgements

Funding

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this